Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1078-0432.CCR-06-1104v1
12/12/3661    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelloff, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelloff, G. J.
Related Collections
Right arrow Commentary
Right arrow Review
Right arrowCommentary
Clinical Cancer Research Vol. 12, 3661-3697, June 15, 2006
© 2006 American Association for Cancer Research

AACR Task Force Report

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Gary J. Kelloff1, Scott M. Lippman2, Andrew J. Dannenberg3, Caroline C. Sigman4, Homer L. Pearce5, Brian J. Reid6, Eva Szabo1, V. Craig Jordan7, Margaret R. Spitz2, Gordon B. Mills2, Vali A. Papadimitrakopoulou2, Reuben Lotan2, Bharat B. Aggarwal2, Robert S. Bresalier2, Jeri Kim2, Banu Arun2, Karen H. Lu2, Melanie E. Thomas2, Helen E. Rhodes2, Molly A. Brewer9, Michele Follen2, Dong M. Shin10, Howard L. Parnes1, Jill M. Siegfried11, Alison A. Evans7, William J. Blot12, Wong-Ho Chow1, Patricia L. Blount6, Carlo C. Maley8, Kenneth K. Wang13, Stephen Lam14, J. Jack Lee2, Steven M. Dubinett15, Paul F. Engstrom7, Frank L. Meyskens, Jr.16, Joyce O'Shaughnessy17, Ernest T. Hawk1, Bernard Levin2, William G. Nelson18, Waun Ki Hong2 for the AACR Task Force on Cancer Prevention

Authors' Affiliations: 1 National Cancer Institute, Bethesda, Maryland; 2 University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3 Weill Medical College of Cornell University, New York, New York; 4 CCS Associates, Mountain View, California; 5 Eli Lilly & Co., Indianapolis, Indiana; 6 Fred Hutchinson Cancer Research Center, Seattle, Washington; 7 Fox Chase Cancer Center; 8 The Wistar Institute, Philadelphia, Pennsylvania; 9 University of Arizona, Tucson, Arizona; 10 Emory University, Atlanta, Georgia; 11 University of Pittsburgh, Pittsburgh, Pennsylvania; 12 International Epidemiology Institute, Rockville, Maryland; 13 Mayo Clinic, Rochester, Minnesota; 14 British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 15 University of California at Los Angeles, Los Angeles, California; 16 University of California at Irvine, Irvine, California; 17 Baylor Sammons Cancer Center, Texas Oncology, PA, U.S. Oncology, Dallas, Texas; and 18 Johns Hopkins University, Baltimore, Maryland

Requests for reprints: Gary J. Kelloff, National Cancer Institute, Executive Plaza North, Room 6058, 6130 Executive Boulevard, Rockville, MD 20852. Phone: 301-594-0423, Fax: 301-480-3507; E-mail: kelloffg{at}mail.nih.gov.

This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.


Commentary

Progress in Chemoprevention: AACR Task Force Report
Paul F. Engstrom
Clin. Cancer Res. 2006 12: 3645. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
V. A. Papadimitrakopoulou, W. N. William Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, et al.
Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions
Clin. Cancer Res., April 1, 2008; 14(7): 2095 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Gu, X. Song, Y. Dong, H. Cai, E. Walters, R. Zhang, X. Pang, T. Xie, Y. Guo, R. Sridhar, et al.
Vitamin E Succinate Induces Ceramide-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma In vitro and In vivo
Clin. Cancer Res., March 15, 2008; 14(6): 1840 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Fini, E. Hotchkiss, V. Fogliano, G. Graziani, M. Romano, E. B. De Vol, H. Qin, M. Selgrad, C.R. Boland, and L. Ricciardiello
Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines
Carcinogenesis, January 1, 2008; 29(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. N. Hittelman, D. D. Liu, J. M. Kurie, R. Lotan, J. S. Lee, F. Khuri, H. Ibarguen, R. C. Morice, G. Walsh, J. A. Roth, et al.
Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids
J Natl Cancer Inst, November 7, 2007; 99(21): 1603 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hoque, H. L. Parnes, M. E. Stefanek, J. V. Heymach, P. H. Brown, and S. M. Lippman
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research
Cancer Res., October 1, 2007; 67(19): 8989 - 8993.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. G. Vogel
Ontology, Oncology, and Preventive Economies: Developing Drugs for Cancer Prevention
Clin. Cancer Res., September 15, 2007; 13(18): 5227 - 5228.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Arun, V. Valero, C. Logan, K. Broglio, E. Rivera, A. Brewster, G. Yin, M. Green, H. Kuerer, Y. Gong, et al.
Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials
Clin. Cancer Res., August 15, 2007; 13(16): 4943 - 4948.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Lippman and J. V. Heymach
The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention
Clin. Cancer Res., July 15, 2007; 13(14): 4035 - 4041.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell
The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M. D. Davis, P. Kochunov, J. Schoolfield, I-T. Yeh, D. A. Troyer, and R. Ghosh
Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract
Clin. Cancer Res., May 1, 2007; 13(9): 2784 - 2794.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Herberman, H. L. Pearce, S. M. Lippman, B. S. Pyenson, and D. S. Alberts
Cancer Chemoprevention and Cancer Preventive Vaccines--A Call to Action: Leaders of Diverse Stakeholder Groups Present Strategies for Overcoming Multiple Barriers to Meet an Urgent Need
Cancer Res., December 15, 2006; 66(24): 11540 - 11549.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. L. Meyskens Jr.
American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2038 - 2041.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. M. Adhami, F. Afaq, and H. Mukhtar
Insulin-like growth factor-I axis as a pathway for cancer chemoprevention.
Clin. Cancer Res., October 1, 2006; 12(19): 5611 - 5614.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.